Skip to main content

5 Result(s)

within P. Tappenden Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT)

    P. Tappenden, Y. Wang, B. Sharrack, J. Burman, M. Kazmi… in Bone Marrow Transplantation (2020)

  2. No Access

    Article

    Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective

    The National Institute for Health and Care Excellence (NICE) invited Gilead, the company manufacturing ledipasvir-sofosbuvir (LDV/SOF), to submit evidence for the clinical effectiveness and cost effectiveness ...

    P. Thokala, E. L. Simpson, P. Tappenden, J. W. Stevens, K. Dickinson… in PharmacoEconomics (2016)

  3. No Access

    Article

    Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal

    The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer (The Medicines Company) of bivalirudin to submit evidence for its clinical and cost effectiveness within its licensed i...

    E. L. Simpson, P. Fitzgerald, P. Evans, P. Tappenden, N. Kalita… in PharmacoEconomics (2013)

  4. No Access

    Article

    Cost of care for colorectal cancer in Ireland: a health care payer perspective

    Management options for colorectal cancer have expanded in recent years. We estimated average lifetime cost of care for colorectal cancer in Ireland in 2008, from the health care payer perspective.

    L. Tilson, L. Sharp, C. Usher, C. Walsh… in The European Journal of Health Economics (2012)

  5. No Access

    Article

    Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis

    Treatment options for secondary progressive multiple sclerosis (SPMS) are limited. Mitoxantrone is routinely used to stabilize disease progression; however, evolving evidence suggests clinical benefit from int...

    P Tappenden, R Saccardi, C Confavreux, B Sharrack… in Bone Marrow Transplantation (2010)